Neurogene Launches With $68.5 Million to Advance Gene Therapies for Rare Neurological Diseases

New York-based Neurogene raised $68.5 million in a Series A funding round to support its pipeline of therapeutics aimed at rare neurological diseases.

Neurogene said the funding will be used to advance multiple gene therapy programs into the clinic aimed at these diseases. Among those assets the company will focus its resources on for development is likely to include an adeno-associated virus (AAV) gene therapy for aspartylglucosaminuria (AGU) and CMT4J, two rare neurological diseases.